glp-1 treatment 3 Takeaways from the Landmark Oral 'Switch' Trial for Obesity Care GLP-1 Personalized Treatment for Weight

( G ) Time course of plasma glucose and glucose infusion rates, and endpoint GIR during hyperinsulinemic-euglycemic clamp of Dpp4 GFP ( n = 4) and Dpp4 hep/ ( n = 5) mice

Related Stories Researchers propose simple finger prick test to track metabolic health Study links gut microbes to stronger cancer immunotherapy responses Popular diabetes drugs do not alter the risk of developing a blinding eye condition The hazard ratio (HR) of thyroid cancer in the GLP-1RA group was 1.24 as compared to those prescribed non-GLP-1RA medications

[PubMed] [Google Scholar] 350.Vrang N., Phifer C.B., Corkern M.M., Berthoud H.R

Key Trend: Increasing Focus on Personalized Medicine Accelerates Engineered Exosome Development The increasing trend in the obesity drug market has been the increasing development and uptake of oral formulations which are more convenient than the traditional injectable therapies

This suggests that incretin-based therapies enhance myocardial glucose uptake in DCM

The drug has already been widely adopted in global markets due to its efficacy in glycemic control and additional metabolic benefits